Kala Bio Inc (KALA)

$0.71 +0.05 (7.31%)
Market Cap 4.62M
Revenue (ttm) 0.00
Net Income (ttm) -38.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -10.32
Volume 280,100
Avg Vol 1,364,554
Day's Range N/A - N/A
Shares Out 7.02M
Stochastic %K 41%
Beta -2.22
Analysts Hold
Price Target $1.50

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 996 5252
Fax: 781 642 0399
Address:
1167 Massachusetts Avenue, Arlington, United States
Stmkr
Stmkr Nov. 14 at 4:40 AM
$VTGN Will this stay at just$110M market towards ph3 readout? Or have a $KALA like move towards the readout. With a positive prior study I expect this to run further towards the readout
0 · Reply
Mandi63
Mandi63 Nov. 13 at 5:27 PM
$AEON $AEON Closed at $1.40 three weeks ago….super low float 11.4 million… BROAD FDA APPROVAL NOVEMBER 19TH PRICE TARGET $8.00 2025 $15.00 2026 $ATCH $DJT $KALA $OSCR
0 · Reply
DARKP00L
DARKP00L Nov. 12 at 9:22 PM
$KALA 16:10 on Nov. 12 2025 KALA BIO Received Nasdaq Deficiency Letter #tradeideas
0 · Reply
Mandi63
Mandi63 Nov. 6 at 6:05 PM
$AEON Share Statistics ; Shares Outstanding · 11.64M ; Implied Shares Outstanding · 11.64M ; Float · 8.2M ; % Held by Insiders · 19.11% ; % Held by Institutions · 11.50%. 7 trading days left for BROAD FDA APPROVAL MEETING $EOLS $KALA $LENZ
0 · Reply
Mandi63
Mandi63 Nov. 5 at 2:49 PM
$AEON $AEON $2.00-5.00 FDA BROAD APPROVAL NOVEMBER 19th $LENZ $FEMY $SANA $KALA
1 · Reply
kibli
kibli Nov. 2 at 12:06 AM
$KALA Expect a pump and dump before delisting. Sorry to everybody here. However, I still remember management's trip to Hawaii for the whole company while shareholders were bleeding.
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Nov. 1 at 9:03 PM
$KALA just looked at it today. it hit .60s few days back
0 · Reply
Investor203
Investor203 Oct. 30 at 7:00 PM
$INTS where is $JNJ or $KALA .
0 · Reply
Alfred_Penny_worth
Alfred_Penny_worth Oct. 29 at 3:01 PM
@ZacksResearch, why do you have $KALA rated as a buy: https://www.zacks.com/stock/quote/KALA despite this kind of fundamental horror?: https://www.marketwatch.com/story/kala-bio-faces-foreclosure-00762ccd?gaa_at=eafs&gaa_n=AWEtsqeNIbNVmfkSDMjp7JpS1Xkc2YSB5Gk0VaGHGDNqs3ByVqZlWdWxL6ZOaeIjX04%3D&gaa_ts=69022fda&gaa_sig=XE7E8DfSAwVElDuIk7hJzcLGS90zWzCH2asC2WMKVTUJB80x7r8su1LSd3RdhDPQUfRUzPH3btMC7wy7BTvndw%3D%3D
0 · Reply
Komba
Komba Oct. 24 at 7:12 AM
$AIRE also watching $KALA
0 · Reply
Latest News on KALA
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Sep 29, 2025, 12:00 PM EDT - 6 weeks ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 3 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:00 AM EDT - 3 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jul 9, 2025, 8:00 AM EDT - 4 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Announces Chief Executive Officer Transition

Feb 12, 2025, 8:00 AM EST - 9 months ago

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 11 months ago

KALA BIO Announces $10,750,000 Private Placement

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 19, 2024, 4:01 PM EST - 1 year ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Participate in Upcoming Investor Conferences in August

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 23, 2022, 12:01 AM EDT - 3 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 10:54 AM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 16, 2022, 7:00 AM EDT - 3 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 9, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 2, 2022, 1:25 PM EDT - 3 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

May 1, 2022, 9:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Apr 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 12:10 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Stmkr
Stmkr Nov. 14 at 4:40 AM
$VTGN Will this stay at just$110M market towards ph3 readout? Or have a $KALA like move towards the readout. With a positive prior study I expect this to run further towards the readout
0 · Reply
Mandi63
Mandi63 Nov. 13 at 5:27 PM
$AEON $AEON Closed at $1.40 three weeks ago….super low float 11.4 million… BROAD FDA APPROVAL NOVEMBER 19TH PRICE TARGET $8.00 2025 $15.00 2026 $ATCH $DJT $KALA $OSCR
0 · Reply
DARKP00L
DARKP00L Nov. 12 at 9:22 PM
$KALA 16:10 on Nov. 12 2025 KALA BIO Received Nasdaq Deficiency Letter #tradeideas
0 · Reply
Mandi63
Mandi63 Nov. 6 at 6:05 PM
$AEON Share Statistics ; Shares Outstanding · 11.64M ; Implied Shares Outstanding · 11.64M ; Float · 8.2M ; % Held by Insiders · 19.11% ; % Held by Institutions · 11.50%. 7 trading days left for BROAD FDA APPROVAL MEETING $EOLS $KALA $LENZ
0 · Reply
Mandi63
Mandi63 Nov. 5 at 2:49 PM
$AEON $AEON $2.00-5.00 FDA BROAD APPROVAL NOVEMBER 19th $LENZ $FEMY $SANA $KALA
1 · Reply
kibli
kibli Nov. 2 at 12:06 AM
$KALA Expect a pump and dump before delisting. Sorry to everybody here. However, I still remember management's trip to Hawaii for the whole company while shareholders were bleeding.
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Nov. 1 at 9:03 PM
$KALA just looked at it today. it hit .60s few days back
0 · Reply
Investor203
Investor203 Oct. 30 at 7:00 PM
$INTS where is $JNJ or $KALA .
0 · Reply
Alfred_Penny_worth
Alfred_Penny_worth Oct. 29 at 3:01 PM
@ZacksResearch, why do you have $KALA rated as a buy: https://www.zacks.com/stock/quote/KALA despite this kind of fundamental horror?: https://www.marketwatch.com/story/kala-bio-faces-foreclosure-00762ccd?gaa_at=eafs&gaa_n=AWEtsqeNIbNVmfkSDMjp7JpS1Xkc2YSB5Gk0VaGHGDNqs3ByVqZlWdWxL6ZOaeIjX04%3D&gaa_ts=69022fda&gaa_sig=XE7E8DfSAwVElDuIk7hJzcLGS90zWzCH2asC2WMKVTUJB80x7r8su1LSd3RdhDPQUfRUzPH3btMC7wy7BTvndw%3D%3D
0 · Reply
Komba
Komba Oct. 24 at 7:12 AM
$AIRE also watching $KALA
0 · Reply
Stocktweeties
Stocktweeties Oct. 24 at 4:03 AM
$KALA Guys please be careful here! It seems that Kala has no intention of distributing any funds to shareholders/stockholders following the foreclosure or potential dissolution. Please trade carefully! NFA
0 · Reply
Bazzzigar
Bazzzigar Oct. 23 at 6:49 PM
$KALA AEMD
0 · Reply
realisticgerman
realisticgerman Oct. 23 at 4:23 PM
$KALA it s about time .. to
0 · Reply
Mreg890307
Mreg890307 Oct. 23 at 12:11 AM
$KALA i was hoping this will get back up but i see they have not cash left, they have a debts and a future deslisting from nasdaq, if this happen all your money will go to a black hole
0 · Reply
mastertrader7
mastertrader7 Oct. 22 at 2:21 PM
$KALA dead cat bounce is over kids. Get out and save your sanity
0 · Reply
Bazzzigar
Bazzzigar Oct. 22 at 1:25 PM
$KALA RS soon
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Oct. 21 at 7:25 PM
$EPWK $JEM $ADVB $KALA $BYND
1 · Reply
Mreg890307
Mreg890307 Oct. 21 at 6:54 PM
$KALA
0 · Reply
Sedmica82
Sedmica82 Oct. 21 at 5:23 PM
$KALA
2 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Oct. 21 at 3:30 PM
$EPWK $JEM $ADVB $KALA $BYND
0 · Reply
Bazzzigar
Bazzzigar Oct. 21 at 11:11 AM
$KALA $0.74?
0 · Reply